|
Available Programs and Courses
FOR Physician
|
|
A complete listing of currently available online programs is provided below. To view course materials click an available viewing format provided with each listing (PDF, HTML, Interactive). To access online exams and claim credit you must be registered and logged in. To add courses to your "MyAR Archives" user account select the "Add To Cart" button provided with each course title and follow the prompts.
|
A Practical Approach to MR Imaging: Stability or High Relaxivity?
|
|
Released:
June 22, 2022
•Expires:
June 30, 2024
|
CE credits:
1.0
• Cost:
$0.00
|
|
Faculty:
Howard Rowley
|
In this CME/CE accredited program Dr. Howard Rowley reviews important efficacy considerations of the FDA approved gadolinium-based contrast agents (GBCAs), including clinical utility, safety issues, and practical approaches for selecting a GBCA when considering patient history, pathology and related risks.
Following Dr. Rowley's presentation, Dr. Rowley joins a panel of MR imaging experts in discussion about this important topic, followed by a moderated Q & A session with audience participation.
Educational Objectives:
At the completion of this activity, participants should be able to:
-
List the key considerations in the choice of GBCAs, while balancing safety and efficacy.
-
Describe the transient effects of T1 and T2 relaxation during a GBCA bolus.
-
Understand the impact of high relaxivity gadolinium agents vs macrocyclic agents.
-
Design MRI protocols to optimize exam efficiency and enhanced lesion detection.
-
Implement GBCA protocols for special patient populations after considering risk assessment.
This program is made possible through an unrestricted educational grant from Bracco Diagnostics, Inc.
|
|
|
|
|
MR Contrast Agents: A Review of the Current Agents & Their Safety Profile
|
|
Released:
December 01, 2020
•Expires:
November 30, 2022
|
CE credits:
1.0
• Cost:
$0.00
|
|
Faculty:
Lawrence N. Tanenbuam, MD, FACR
|
Today, with such a wide selection of gadolinium-based contrast agents available to choose from; imaging professionals must be aware of the chemical make-up when selecting a MR agent for a particular exam.
This CME/CE accredited webinar with Lawrence N. Tanenbaum, MD, FACR, provides a review of the currently available FDA-approved MR contrast agents and their safety profiles. Following Dr. Tanenbaum's presentation questions from the audience were addressed in a moderated Q&A session.
Educational Objectives:
At the completion of this activity, participants should be able to:
-
Discuss the available FDA-approved contrast agents in the US market.
-
Review the chemical structure, indications, and safety profile of these agents.
-
Develop a better understanding of how selection of contrast can affect patient outcomes.
Supported through an unrestricted educational grant from GE Healthcare
|
|
|
|
|
MR Contrast Selection & Utilization in Pediatric & Neonatal Patients
|
|
Released:
November 22, 2021
•Expires:
November 30, 2023
|
CE credits:
1.0
• Cost:
$0.00
|
|
Faculty:
Chetan C. Shah, MD, MBA
|
In MR Imaging, a careful review of the safety criteria for the selection of a Gadolinium-based Contrast Agents (GBCAs) should be considered for pediatric and neonatal patients. The program will provide a comprehensive review of the supporting research that addresses Gadolinium selection in this special patient population. Both chronic and long-term effects of GBCAs will be discussed.
As a Pediatric Neuroradiologist, Dr. Shah is uniquely qualified to share his experience which includes a discussion of risk vs benefits, supported by practical protocols for the administration of MR contrast; including limiting the amount of contrast given to patients that may receive several lifetime doses. Following the presentation, the audience is invited to join Dr. Shah for an interactive Q & A session.
Educational Objectives:
At the completion of this activity, participants should be able to:
-
Explain the differences between available MR contrast agents and any associated adverse events
-
Improve clinical management decisions about when to administer MR contrast (risk vs benefit)
-
Apply FDA guidelines regarding MRI contrast agents to clinical practice.
Made possible through an unrestricted educational grant from Bracco Diagnostics, Inc.
|
|
|
|